Summary of Antengene's Conference Call Company Overview - **Company**: Antengene - **Industry**: Biotechnology, specifically focusing on T-cell engagers and immunology - **Key Product**: ATG-201, a CD19/CD3 bispecific T-cell engager for autoimmune diseases Key Points from the Conference Call Licensing Agreement with UCB - Antengene has entered a global licensing agreement with UCB for ATG-201, marking a significant milestone as the first program from the AnTenGager platform to secure a global partnership [1] - UCB will receive worldwide exclusive rights to ATG-201, while Antengene will receive $80 million in upfront and near-term milestone payments, with potential future payments of approximately $1.1 billion, excluding royalties [6][7] - The total potential deal value is approximately $1.2 billion [6] Strategic Rationale - The partnership aims to leverage Antengene's discovery and early clinical execution capabilities alongside UCB's expertise in immunology and global commercialization [6] - UCB's established immunology franchise and strong clinical execution track record (86% phase 3 success rate) provide a solid foundation for advancing ATG-201 [8] AnTenGager Platform - The AnTenGager platform is designed to create differentiated T-cell engagers, addressing limitations of first-generation T-cell engagers, such as suboptimal targeting and safety concerns [9][10] - The platform incorporates a proprietary CD3 sequence and a steric hindrance masking design, enhancing targeting efficacy and safety [10][12] - Antengene has a robust pipeline of T-cell engager programs targeting various diseases, including autoimmune diseases and solid tumors [16][18] Clinical Development and Pipeline - Antengene has conducted clinical trials across five regions, securing 32 IND approvals and advancing six first-in-human programs globally [4] - The company plans to submit clinical trial applications for ATG-201 in China and Australia in Q1 2026, with the first-in-human studies to be conducted by Antengene [6][31] - Other programs in the pipeline include ATG-106 for ovarian and kidney cancers, ATG-112 for gynecological cancers, and ATG-110 for colorectal cancer, with IND submissions planned for 2027 [16][17][18] Financial Position and Future Outlook - Antengene is well-funded, with increasing revenue from approved products in Asia-Pacific markets and additional revenue from partnerships [42] - The company aims to maximize the global impact of its innovative medicines while maintaining a focus on strategic partnerships [34][70] - Antengene is entering a new phase of growth, supported by a pivotal stage pipeline and continued scientific innovation [24][25] Additional Insights - The company remains open to both single asset and multiple asset partnership deals, emphasizing flexibility in collaboration models [33][34] - The focus for the phase 1 trial of ATG-201 will be on autoimmune diseases, with considerations for other high unmet medical needs [47][52] - Antengene's proprietary CD3 sequence is designed to minimize excessive cytokine release and T-cell exhaustion, enhancing safety and efficacy [64][65] Conclusion Antengene's strategic partnership with UCB for ATG-201 represents a significant advancement in its pipeline, leveraging both companies' strengths to enhance the development of innovative therapies for autoimmune diseases. The AnTenGager platform's unique design and the company's robust pipeline position Antengene for continued growth and leadership in the biotechnology sector.

Trip.com Group Ltd (TCOM.O) Conference Call Summary Company Overview - **Company**: Trip.com Group Ltd (TCOM.O) - **Industry**: Online Travel Agency (OTA) - **Market**: Asia Pacific - **Current Price Target**: US$75.00, revised from US$87.00 [1] Key Points Financial Performance - **Solid Earnings**: TCOM reported strong earnings with a healthy outlook for 2026, driven by robust travel demand [2] - **Revenue Growth**: Management expects revenue growth of 12-17% in Q1 2026, with a high likelihood of reaching the upper end of this guidance [2] - **Booking Growth**: QTD bookings are up 60%, with domestic hotel bookings in China growing at double-digit rates [2] - **Segment Performance**: - Hotel and packaged tours are growing in the high teens YoY - Transportation growth is projected at 8-13% [2] International Expansion - **International Business Growth**: International business accounted for approximately 40% of total revenue in 2025, up from 35% in 2024, with inbound travel showing close to triple-digit growth [3] - **Market Strategy**: The mobile-first and one-stop solution strategy is yielding positive results in APAC and Middle East markets [3] Regulatory Environment - **Regulatory Investigation**: No updates on the regulatory front; TCOM is cooperating fully with regulators. The ongoing investigation has led to a higher WACC assumption of 11.2% [5] - **Impact on Earnings**: Revenue forecasts for 2026/27 have been raised by 1%, but EPS estimates have been cut by 3-4% due to increased operating expenses [5] AI and Technology - **AI Development**: Management views AI as a catalyst for OTA businesses rather than a threat, emphasizing the importance of proprietary data and service capabilities [4] - **Investment in AI**: TCOM continues to invest in vertical AI technology to enhance travel-related search results [4] Market Position and Valuation - **Market Share**: TCOM is gaining market share due to post-COVID tailwinds and a shift in consumer spending towards travel [25] - **Valuation Metrics**: The new price target of US$75 implies a P/E ratio of 18x for 2026 and 16x for 2027 [5] - **Stock Rating**: The stock is rated as "Overweight" with a significant upside potential of 40% from the current price [6] Risks and Considerations - **Market Risks**: Potential risks include rising competition in the domestic market and macroeconomic uncertainties affecting travel demand [37] - **Investment Risks**: The ongoing regulatory investigation poses a risk to the company's operational outlook and financial performance [5] Additional Insights - **Share Repurchase Program**: TCOM announced a US$5 billion share repurchase program, representing over 10% of its market cap at the time of announcement [25] - **Long-term Growth**: The company is well-positioned to benefit from multiple growth engines, including domestic and outbound travel, as well as international expansion [25] This summary encapsulates the key insights from the conference call, highlighting the company's financial performance, growth strategies, regulatory environment, and market positioning.

卫龙美味 20260303 摘要 2026 年业绩预期乐观：预计收入增长 15%-20%，辣条业务转正，魔 芋业务高增；利润增速因规模效应及成本红利有望跑赢收入。 盈利修复核心变量：2026 年魔芋原材料成本预计明显下降，叠加高毛 利蔬菜制品占比提升及新老工厂切换带来的效率增益，毛利率具备修复 空间。 产品矩阵与竞争格局：蔬菜制品已成第一大业务（25H1 毛利 46.6%）；魔芋零食 CR3 达 75%，卫龙份额超 50%稳居第一，但面临 盐津铺子等品牌冲击。 渠道下沉与终端赋能：线下覆盖网点超 58 万个，单点 SKU 由 9.6-12.5 个提升至 16-22.8 个；重点布局增速更快的下沉市场及零食量贩专卖店 渠道。 魔芋品类创新趋势：香辣味仍为主流（占比>35%），麻酱口味快速崛 起（占比>25%）；公司 2026 年将推进麻酱、牛肝菌等新品至流通渠 道。 股东回报与估值支撑：随资本开支高峰结束，自由现金流显著改善，分 红比例有望延续高位；2026 年预测 PE 不足 15 倍，具备估值修复潜力。 Q&A 卫龙美味的公司定位、组织架构与全国化布局进展如何？ 卫龙美味是国内头部辣味休闲零食企业之一，集研 ...

Asia Pacific Equity Research 27 February 2026 China Artificial Intelligence CNY-to-date: model agentization with accelerating token consumption, raise Zhipu/MiniMax PT to HK$800/1000 Shares of Knowledge Atlas (Zhipu AI) and MiniMax have risen five-fold since IPO (vs HSI +4.3%), driven by strong investor demand for pure-play GenAI exposure and a broadening narrative that 'AI will disrupt everything'. Beyond sentiment, we see the CNY model release window marking a step change in making monetization dynamics m ...

March 2, 2026 10:10 AM GMT XPeng Inc. | Asia Pacific VLA 2.0 - A bold leap forward to capture the X factor Key Takeaways XPeng officially unveiled its long-awaited VLA 2.0, with 12x faster model inference vs. the previous generation. Per XPeng, it will enable a smoother, more efficient, human-like driving experience with better handling of complex scenarios and corner cases. VLA 2.0 should soon be available on P7, G7, and X9 Ultra in 2H of March, while other models will receive the OTA update in April. Time ...

2 March 2026 | 7:35AM HKT Equity Research Laopu Gold (6181.HK): Conducts 20-30% price hike following strong peak season; Buy On Feb 28th, Laopu conducted a 20-30% price hike (mainly falls into 25-30% range), which based on our conversation with investors, appears on average slightly higher than expectation. By category, pure gold products saw higher price hike magnitude. In our view, this helps to protect the company's GPM which management targets for 40% in 2026, vs. in 2025. Laopu's price was generally be ...

石药集团 20260302 摘要 石药集团创新管线进入兑现期，重点布局肿瘤、减肥/代谢及小核酸领域， 与阿斯利康达成 185 亿美金合作，首付款 12 亿美金，强化其全球化交 易能力和里程碑兑现预期。 石药集团在小分子、ADC 及生物药方向均有深入布局，多个项目处于全 球研发前列，部分具备 first-in-class 属性，EGFR ADC、CD47/CD20 双抗等展现 Best-in-class 潜力。2026 年将迎来早期临床数据密集读出 窗口。 EGFR ADC (6,010) 在 EGFR 突变非小细胞肺癌及后线适应症上体现出 潜在 Best-in-class 特征，并具备广谱 ADC 属性，覆盖多种实体瘤。公 司正探索前线联合治疗，2026 年或有联合治疗数据读出。 CD47/CD20 双特异性融合蛋白 (601) 在血液瘤中显示出较好疗效与安 全性，并有望拓展至 B 细胞相关自身免疫性疾病领域。 PD-1/L15 融合蛋白 (108) 主要针对尿路上皮癌方向的非肌层浸润性膀 胱癌，聚焦 BCG 不响应患者人群，预计 2026 年将发布部分数据。 与阿斯利康在 GLP-1 方向的合作是平台型合作 ...

Flash | 01 Mar 2026 15:46:27 ET │ 14 pages Montage Technology (688008.SS) 4Q25 GPM Expansion Offsets Softer Revenue; AI Infrastructure Thesis Remains Intact CITI'S TAKE Montage disclosed on Feb 27 further details of its preliminary FY25 results. 4Q25 revenue grew 31% to Rmb1.4bn, at 6%/9% below BBG consensus/Citi estimates. Interconnect chips GPM rose 2ppt QoQ (+4.4ppt YoY) to 67.8% in 4Q25 driven by improved product mix. R&D expenses rose 80% YoY to Rmb380mn for new product development. 4Q25 net profit cam ...

Summary of China Cosmetics Conference Call Industry Overview - The focus is on the **anti-aging beauty market** in China, which includes traditional anti-aging skincare, medical aesthetics (MA), and dermocosmetics. - The market is expected to grow at a **high single-digit CAGR** over the period from 2025 to 2030, with medical aesthetics and dermocosmetics leading at **9%** and anti-aging skincare at **6%** [1][22]. Key Insights Market Penetration and Demographics - The current penetration of the MA market in China is low, estimated at **5%** for the core consumer group aged **20-60**, compared to **10%-20%** in developed markets. It is expected to rise to **8%** by **2030E**, supporting a **10% CAGR** for MA users [2][22]. - Anti-aging skincare is seeing earlier adoption among younger consumers, with approximately **40%** of this demographic engaging with the category, which is expected to drive further expansion [2][22]. Pricing Dynamics - More resilient pricing is anticipated from **2026E** due to stricter regulations and healthier competition, with limited supply tailwinds favoring recombinant collagen. The MA market has experienced sharp price reductions due to intense competition, but future pricing is expected to stabilize [3][22]. - Factors contributing to this stabilization include more accessible pricing in China and a narrower price gap with Korea following recent policy changes [3][22]. Company Recommendations - **Forest Cabin** is initiated with a **Buy** rating, expected to benefit from growth in oil-based anti-aging skincare, with a projected **48% sales CAGR** from **2022-2025E** and **32%/29% sales/NP CAGR** from **2025-2028E** [4][22]. - **Giant Biogene** is also rated **Buy** due to its integrated value chain from MA to dermocosmetics, enhancing R&D and brand recognition [4][22]. - **Proya** is viewed as a domestic leader in the anti-aging sector but is rated **Neutral** pending further evidence of the new management's execution track record [4][22]. Market Growth Projections - The overall anti-aging market in China is projected to grow from **RMB 214 billion** in **2024E** to **RMB 398 billion** by **2030E**, reflecting a **CAGR of 8%** [20][22]. - Medical aesthetics is expected to contribute significantly to this growth, with a **10.3% volume CAGR** over the same period, despite ongoing pricing pressures in certain categories [17][22]. Additional Insights - The report emphasizes the importance of companies with larger sales exposure to growth segments, stronger market positions, and better operational execution, including R&D capabilities [10][22]. - The anti-aging skincare segment is projected to see a shift towards functionalities beyond basic moisturizing, with penetration expected to increase from **25.6% to 29.0%** from **2025 to 2030E** [19][22]. Conclusion - The anti-aging beauty market in China presents significant growth opportunities driven by demographic shifts, evolving consumer perceptions, and technological advancements. Companies like Forest Cabin and Giant Biogene are well-positioned to capitalize on these trends, while pricing dynamics and market penetration will play crucial roles in shaping the competitive landscape.

Company and Industry Summary Company Overview - The company focuses on AI, Data, and Agent as core components, providing end-to-end data services and is responsible for delivery results. Initially concentrated on the Southeast Asian financial market, it has expanded into 7-8 industries including retail, urban operations, and healthcare. Clients include private equity funds, public funds, and large enterprises like China Mobile [2][3] Core Business Model - The revenue model primarily consists of annual fees charged per module, supplemented by a transaction model. The company has high customer stickiness due to continuous delivery and support. In the first half of 2025, revenue was approximately 200 million yuan, although this figure is affected by client acceptance delays [2][6][7] Competitive Advantages - The company does not directly own client data, allowing clients to choose their front-end tools and models. Its strength lies in transforming heterogeneous and dirty data into high-quality usable data and providing adaptation and tuning capabilities between data and large models, creating deep binding relationships, especially in high-demand industries like finance [2][8] Industry Expansion Strategy - The company adopts a top-down expansion strategy, entering 1-2 new industries each year, starting with leading clients for customized delivery and gradually increasing standardization. Industries that are expected to take 3-5 years or 5-7 years to converge will be postponed. In 2026, the focus will be on investing in a robot training data platform and commercial aerospace [2][10] Project Delivery and Client Engagement - Typical projects cover the entire process from data acquisition, cleaning, standardization, to modeling, transforming large amounts of heterogeneous and dirty data into high-quality data. Delivery methods depend on client needs and can support remote delivery if data formats are adequate [4][11] Research and Development - Approximately 67% of the workforce is dedicated to R&D, with around 320 personnel. The company’s tools and engineering capabilities are reusable across industries, but entering new industries requires learning specific industry data and bringing in expert personnel [12] Pricing and Revenue Growth - The current pricing model is primarily based on annual fees per module, with exploration into backend revenue sharing based on value creation. Future considerations may include pricing based on traffic or tokens. The goal is to gradually align gross margins across industries towards the financial sector's level of around 80% [13] Client Concentration and Risk - The current client concentration is not significantly high, with revenue derived from both financial and diversified industry clients. As the amount from diversified clients increases, overall revenue is expected to rise [9] Market Trends and Client Acquisition - The company relies on client referrals for customer acquisition, with low sales personnel costs. There is a notable increase in interest from state-owned enterprises in AI, shifting from hardware-focused investments to recognizing the value of data [19] Financial Performance and Future Outlook - The company anticipates considerable growth in 2025, with expectations to achieve breakeven and generate profit in 2026. Current trends and forecasts indicate a normal and relatively optimistic performance [20]